Company profile

Shanghai Yinnuo Pharmaceutical Technology

Peptide therapeutics

Privately held: no public share price · China

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
efsubaglutide alfa
Phase 3
GLP-1 receptorProtein / enzyme therapeutic
Obesity
SupaglutideNo recent activity
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.